Renin-angiotensin system (RAS) blockers, including angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs), have been pivotal in the management of proteinuria in DKD and non-diabetic CKD [28, 29]. This evidence concerns the gene ACE and diabetic kidney disease.